Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development expense	$ 20,071	$ 32,774
General and administrative	11,318	2,955
Total operating expenses	31,389	35,729
Loss from operations	(31,389)	(35,729)
Other income (expense):
Interest income	9	4
Change in fair value of derivative liability		(1,100)
Total other income (expense)	9	(1,096)
Net loss and comprehensive loss	$ (31,380)	$ (36,825)
Net loss per common share - basic and diluted	$ (0.97)	$ (27.26)
Weighted average shares of common stock outstanding - basic and diluted	32,316,689	1,350,743